Navigation Links
Lilly Names Melissa Barnes Chief Ethics and Compliance Officer and Senior Vice President; Announces Retirement of Anne Nobles

INDIANAPOLIS, Oct. 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Melissa Barnes will be promoted to chief ethics and compliance officer and senior vice president of enterprise risk management effective Jan. 1, 2013. Barnes will replace Anne Nobles, who will retire at the end of the year.

Barnes, vice president and deputy general counsel, is currently responsible for litigation, compliance and specialty legal areas, including regulatory and human resources. In her new role, Barnes will report to John Lechleiter, Ph.D., chairman, president and CEO, and will serve on the company's executive committee.

"Melissa's legal background and extensive experience at Lilly make her the right person to assume this important role within our company," said Lechleiter.  "Lilly is committed to conducting our business with the highest level of integrity and in full compliance with the laws and regulations that govern our operations. Having someone with Melissa's qualifications lead our ethics and compliance organization is evidence of this commitment."  

Barnes is a graduate of Harvard Law School. She joined the company in 1994 and has served in a number of legal and business positions at Lilly, specializing in legal work related to compliance, litigation, human resources, regulatory, business management strategy, and global marketing and sales.

Nobles joined Lilly in 1990 and has served in various leadership positions, including vice president of corporate affairs.  She became Lilly's chief compliance officer in 2007 and has served on the company's executive committee since 2009.

"Anne has provided critical leadership at a very important time for our company," said Lechleiter. "Her contributions have been instrumental in building a comprehensive company-wide ethics and compliance program. She has worked closely with Lilly business leaders to ensure that compliance is effectively integrated into our business plans and our day-to-day activities."

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at  C-LLY



SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Celebrates 18th Consecutive Year as One of Working Mothers 100 Best Companies
2. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
3. Lilly Announces Results From Lung Cancer Study
4. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
5. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
6. U.S. Court of Appeals Upholds Validity of Lillys Alimta Compound Patent
7. Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
8. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
9. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
10. Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
11. Lilly Confirms Date and Conference Call for Second-Quarter 2012 Financial Results Announcement
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their ... Eyeglasses . , Millions of individuals in the United States and Canada wear eyeglasses. ... way to both correct vision and make a fashion statement. Even celebrities use glasses ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
Breaking Medicine News(10 mins):